



Clinical trial results:

Study to evaluate GSK Biologicals' Herpes Zoster vaccine GSK1437173A in adults aged ≥ 50 years

Summary

EudraCT number	2008-000367-42
Trial protocol	ES FI FR DE GB SE EE IT CZ
Global end of trial date	27 July 2015

Results information

Result version number	v2 (current)
This version publication date	03 March 2021
First version publication date	10 August 2016
Version creation reason	<ul style="list-style-type: none">• Correction of full data set Results have been amended to account for consistency with other registries.

Trial information

Trial identification

Sponsor protocol code	110390
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01165177
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 May 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	09 May 2014
Global end of trial reached?	Yes
Global end of trial date	27 July 2015
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate VE in the prevention of HZ compared to placebo in adults 50 YOA, as measured by the reduction in herpes zoster (HZ) risk.

Protection of trial subjects:

The vaccine/product recipients were to be observed closely for at least 30 minutes, with appropriate medical treatment readily available in case of a rare anaphylactic reaction following the administration of vaccine/product. Vaccines/products were administered by qualified and trained personnel. Vaccines/products were administered only to eligible subjects that had no contraindications to any components of the vaccines/products. Subjects were followed-up for 30 days after the last vaccination/product administration.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 August 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 418
Country: Number of subjects enrolled	Brazil: 634
Country: Number of subjects enrolled	Canada: 631
Country: Number of subjects enrolled	Czech Republic: 905
Country: Number of subjects enrolled	Estonia: 1110
Country: Number of subjects enrolled	Finland: 1422
Country: Number of subjects enrolled	France: 624
Country: Number of subjects enrolled	Germany: 789
Country: Number of subjects enrolled	Hong Kong: 470
Country: Number of subjects enrolled	Italy: 358
Country: Number of subjects enrolled	Japan: 577
Country: Number of subjects enrolled	Korea, Republic of: 539
Country: Number of subjects enrolled	Mexico: 914
Country: Number of subjects enrolled	Spain: 1057
Country: Number of subjects enrolled	Sweden: 1013
Country: Number of subjects enrolled	Taiwan: 1281
Country: Number of subjects enrolled	United Kingdom: 619
Country: Number of subjects enrolled	United States: 2068

Worldwide total number of subjects	15429
EEA total number of subjects	7897

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	9618
From 65 to 84 years	5628
85 years and over	183

Subject disposition

Recruitment

Recruitment details:

Apportionment of approximately 20-25% of the ≥ 70 YOA cohort to persons ≥ 80 YOA ensures that this particularly vulnerable population is adequately represented.

Pre-assignment

Screening details: -

Pre-assignment period milestones

Number of subjects started	15429
----------------------------	-------

Number of subjects completed	15405
------------------------------	-------

Pre-assignment subject non-completion reasons

Reason: Number of subjects	Study vaccine not received: 24
----------------------------	--------------------------------

Period 1

Period 1 title	Overall Study (overall period)
----------------	--------------------------------

Is this the baseline period?	Yes
------------------------------	-----

Allocation method	Randomised - controlled
-------------------	-------------------------

Blinding used	Double blind
---------------	--------------

Roles blinded	Investigator, Assessor, Subject
---------------	---------------------------------

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	GSK1437173A Group
------------------	-------------------

Arm description:

Subjects received herpes zoster subunit vaccine (gE/AS01B vaccine: GSK1437173A) according to a 0, 2-month schedule.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	GSK1437173A
--	-------------

Investigational medicinal product code	
--	--

Other name	gE-AS01B
------------	----------

Pharmaceutical forms	Powder and solvent for suspension for injection
----------------------	---

Routes of administration	Intramuscular use
--------------------------	-------------------

Dosage and administration details:

The study product was administered according to a 0, 2-month schedule.

Arm title	Placebo Group
------------------	---------------

Arm description:

Subjects received saline solution (NaCl solution) as control according to a 0, 2-month schedule.

Arm type	Placebo
----------	---------

Investigational medicinal product name	Placebo
--	---------

Investigational medicinal product code	
--	--

Other name	Saline solution
------------	-----------------

Pharmaceutical forms	Solution for injection
----------------------	------------------------

Routes of administration	Intramuscular use
--------------------------	-------------------

Dosage and administration details:

The study product was administered according to a 0, 2-month schedule.

Number of subjects in period 1^[1]	GSK1437173A Group	Placebo Group
Started	7695	7710
Completed	6773	6808
Not completed	922	902
Suspected HZ episode	-	2
Consent withdrawn by subject	368	354
Non-serious adverse events	30	18
Migrated/ moved from study area	48	43
Serious adverse events	227	235
Lost to follow-up	183	194
Other unspecified reasons	47	35
Protocol deviation	19	21

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Out of the 15429 subjects enrolled in the trial, 24 were assigned codes but did not receive vaccination, hence they were excluded from the study start.

Baseline characteristics

Reporting groups

Reporting group title	GSK1437173A Group
Reporting group description:	
Subjects received herpes zoster subunit vaccine (gE/AS01B vaccine: GSK1437173A) according to a 0, 2-month schedule.	
Reporting group title	Placebo Group
Reporting group description:	
Subjects received saline solution (NaCl solution) as control according to a 0, 2-month schedule.	

Reporting group values	GSK1437173A Group	Placebo Group	Total
Number of subjects	7695	7710	15405
Age categorical			
Units: Subjects			
Age continuous			
Age continuous description			
Units: years			
arithmetic mean	62.4	62.3	
standard deviation	± 9	± 9	-
Gender categorical			
Gender categorical description			
Units: Subjects			
Female	4709	4711	9420
Male	2986	2999	5985

End points

End points reporting groups

Reporting group title	GSK1437173A Group
Reporting group description: Subjects received herpes zoster subunit vaccine (gE/AS01B vaccine: GSK1437173A) according to a 0, 2-month schedule.	
Reporting group title	Placebo Group
Reporting group description: Subjects received saline solution (NaCl solution) as control according to a 0, 2-month schedule.	
Subject analysis set title	GSK1437173A 50-59 YOA Group
Subject analysis set type	Sub-group analysis
Subject analysis set description: Subjects aged between 50 and 59 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.	
Subject analysis set title	GSK1437173A 60-69 YOA Group
Subject analysis set type	Sub-group analysis
Subject analysis set description: Subjects aged between 60 and 69 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.	
Subject analysis set title	GSK1437173A Over 70 YOA Group
Subject analysis set type	Sub-group analysis
Subject analysis set description: Subjects aged above 70 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.	
Subject analysis set title	GSK1437173A Overall Ages Group
Subject analysis set type	Sub-group analysis
Subject analysis set description: Subjects aged over 50 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.	
Subject analysis set title	Placebo 50-59 YOA Group
Subject analysis set type	Sub-group analysis
Subject analysis set description: Subjects aged between 50 and 59 years of age (YOA), receiving placebo according to a 0, 2-month schedule.	
Subject analysis set title	Placebo 60-69 YOA Group
Subject analysis set type	Sub-group analysis
Subject analysis set description: Subjects aged between 60 and 69 years of age (YOA), receiving placebo according to a 0, 2-month schedule.	
Subject analysis set title	Placebo Over 70 YOA Group
Subject analysis set type	Sub-group analysis
Subject analysis set description: Subjects aged above 70 years of age (YOA), receiving placebo according to a 0, 2-month schedule.	
Subject analysis set title	Placebo Overall Ages Group
Subject analysis set type	Sub-group analysis
Subject analysis set description: Subjects aged over 50 years of age (YOA), receiving placebo according to a 0, 2-month schedule.	

Primary: Number of subjects with confirmed Herpes zoster (HZ) cases

End point title	Number of subjects with confirmed Herpes zoster (HZ) cases
-----------------	--

End point description:

Confirmed HZ cases during the study were assessed in the Modified Total Vaccinated Cohort (mTVc)

End point type	Primary
----------------	---------

End point timeframe:

During the entire study period (3 to 5 year period following Day 0)

End point values	GSK1437173A 50-59 YOA Group	GSK1437173A 60-69 YOA Group	GSK1437173A Over 70 YOA Group	GSK1437173A Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3492	2141	1711	7344
Units: Subjects	3	2	1	6

End point values	Placebo 50-59 YOA Group	Placebo 60-69 YOA Group	Placebo Over 70 YOA Group	Placebo Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3525	2166	1724	7415
Units: Subjects	87	75	48	210

Statistical analyses

Statistical analysis title	Statistical analysis 1
----------------------------	------------------------

Statistical analysis description:

Comparison of vaccine efficacy in prevention of HZ between GSK1437173A 50-59 YOA group and placebo 50-59 YOA group

Comparison groups	Placebo 50-59 YOA Group v GSK1437173A 50-59 YOA Group
Number of subjects included in analysis	7017
Analysis specification	Pre-specified
Analysis type	other ^[1]
P-value	< 0.0001 ^[2]
Method	Poisson exact test
Parameter estimate	Vaccine efficacy
Point estimate	96.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	89.6
upper limit	99.3

Notes:

[1] - Criteria for the vaccine efficacy (VE) objective of herpes zoster subunit (HZ/su) vaccine against herpes zoster (HZ) disease, in the 50-59 YOA age strata : The lower limit (LL) of the two-sided 95% confidence interval (CI) of VE had to be above 10%.

[2] - Two sided exact P-value conditional to number of cases.

Statistical analysis title	Statistical analysis 2
Statistical analysis description: Comparison of vaccine efficacy in prevention of HZ between GSK1437173A over 60-69 YOA group and placebo over 60-69 YOA group	
Comparison groups	Placebo 60-69 YOA Group v GSK1437173A 60-69 YOA Group
Number of subjects included in analysis	4307
Analysis specification	Pre-specified
Analysis type	other ^[3]
P-value	< 0.0001 ^[4]
Method	Poisson exact test
Parameter estimate	Vaccine efficacy
Point estimate	97.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	90.1
upper limit	99.7

Notes:

[3] - Criteria for the VE objective of HZ/su vaccine against herpes zoster disease, in the 60-69 YOA age strata : The lower limit (LL) of the two-sided 95% confidence interval (CI) of VE had to be above 10%.

[4] - Two sided exact P-value conditional to number of cases.

Statistical analysis title	Statistical analysis 3
Statistical analysis description: Comparison of vaccine efficacy in prevention of HZ between GSK1437173A over 70 YOA group and placebo over 70 YOA group	
Comparison groups	GSK1437173A Over 70 YOA Group v Placebo Over 70 YOA Group
Number of subjects included in analysis	3435
Analysis specification	Pre-specified
Analysis type	other ^[5]
P-value	= 0.0001 ^[6]
Method	Poisson exact test
Parameter estimate	Vaccine efficacy
Point estimate	97.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	87.9
upper limit	100

Notes:

[5] - Criteria for the VE objective of HZ/su vaccine against herpes zoster disease, in the 70-79 YOA age strata : The lower limit (LL) of the two-sided 95% confidence interval (CI) of VE had to be above 10%.

[6] - Two sided exact P-value conditional to number of cases.

Statistical analysis title	Statistical analysis 4
----------------------------	------------------------

Statistical analysis description:

Comparison of vaccine efficacy in prevention of HZ between GSK1437173A overall ages group and placebo overall ages group

Comparison groups	Placebo Overall Ages Group v GSK1437173A Overall Ages Group
Number of subjects included in analysis	14759
Analysis specification	Pre-specified
Analysis type	other ^[7]
P-value	< 0.0001 ^[8]
Method	Poisson exact test
Parameter estimate	Vaccine efficacy
Point estimate	97.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	93.7
upper limit	99

Notes:

[7] - Criteria for the VE objective of HZ/su vaccine against herpes zoster disease, in the overall age strata : The lower limit (LL) of the two-sided 95% confidence interval (CI) of VE had to be above 10%.

[8] - Two sided exact P-value conditional to number of cases.

Secondary: Number of subjects with any episodes of Post-Herpetic Neuralgia (PHN)

End point title	Number of subjects with any episodes of Post-Herpetic Neuralgia (PHN)
End point description:	The incidence of PHN was calculated using the modified total vaccinated cohort.
End point type	Secondary
End point timeframe:	During the entire study period (3 to 5 year period following Day 0)

End point values	GSK1437173A 50-59 YOA Group	GSK1437173A 60-69 YOA Group	GSK1437173A Over 70 YOA Group	GSK1437173A Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3491	2140	1709	7430
Units: Subjects	0	0	0	0

End point values	Placebo 50-59 YOY Group	Placebo 60-69 YOY Group	Placebo Over 70 YOY Group	Placebo Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3523	2166	1724	7413
Units: Subjects	8	2	8	18

Statistical analyses

Statistical analysis title	Statistical analysis 1
-----------------------------------	------------------------

Statistical analysis description:

Comparison of vaccine efficacy in prevention of PHN between GSK1437173A 50-59 YOA group and placebo 50-59 YOA group

Comparison groups	GSK1437173A 50-59 YOA Group v Placebo 50-59 YOA Group
Number of subjects included in analysis	7014
Analysis specification	Pre-specified
Analysis type	other ^[9]
P-value	= 0.0081
Method	Poisson exact test
Parameter estimate	Vaccine efficacy
Point estimate	100
Confidence interval	
level	95 %
sides	2-sided
lower limit	40.9
upper limit	100

Notes:

[9] - Criteria for the VE objective of HZ/su vaccine against PostHerpetic Neuralgia (PHN): The lower limit of the 95% CI of VE had to be above 0%

Statistical analysis title	Statistical analysis 2
-----------------------------------	------------------------

Statistical analysis description:

Comparison of vaccine efficacy in prevention of PHN between GSK1437173A 60-69 YOA group and placebo 60-69 YOA group

Comparison groups	Placebo 60-69 YOA Group v GSK1437173A 60-69 YOA Group
Number of subjects included in analysis	4306
Analysis specification	Pre-specified
Analysis type	other ^[10]
P-value	= 0.5097
Method	Poisson exact test
Parameter estimate	Vaccine efficacy
Point estimate	100
Confidence interval	
level	95 %
sides	2-sided
lower limit	-442.8
upper limit	100

Notes:

[10] - Criteria for VE of HZ/su vaccine against PHN: The lower limit of the 95% CI of VE had to be above 0%

Statistical analysis title	Statistical analysis 3
-----------------------------------	------------------------

Statistical analysis description:

Comparison of vaccine efficacy in prevention of PHN between GSK1437173A over 70 YOA group and placebo over 70 YOA group

Comparison groups	GSK1437173A Over 70 YOA Group v Placebo Over 70 YOA Group
-------------------	---

Number of subjects included in analysis	3433
Analysis specification	Pre-specified
Analysis type	other ^[11]
P-value	= 0.0078
Method	Poisson exact test
Parameter estimate	Vaccine efficacy
Point estimate	100
Confidence interval	
level	95 %
sides	2-sided
lower limit	41.4
upper limit	100

Notes:

[11] - Criteria for the VE objective of HZ/su vaccine against PHN: The lower limit of the 95% CI of VE had to be above 0%

Statistical analysis title	Statistical analysis 4
-----------------------------------	------------------------

Statistical analysis description:

Comparison of vaccine efficacy in prevention of PHN between GSK1437173A overall ages group and placebo overall ages group

Comparison groups	Placebo Overall Ages Group v GSK1437173A Overall Ages Group
Number of subjects included in analysis	14843
Analysis specification	Pre-specified
Analysis type	other ^[12]
P-value	< 0.0001
Method	Poisson exact test
Parameter estimate	Vaccine efficacy
Point estimate	100
Confidence interval	
level	95 %
sides	2-sided
lower limit	77.1
upper limit	100

Notes:

[12] - Criteria for the VE objective of HZ/su vaccine against PHN: The lower limit of the 95% CI of VE had to be above 0%

Secondary: Number of subjects with a reduction of duration of severe 'worst' HZ-associated pain

End point title	Number of subjects with a reduction of duration of severe 'worst' HZ-associated pain
-----------------	--

End point description:

Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' Zoster Brief Pain Inventory (ZBPI) questionnaire. The outcome assessed the duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period as measured by the ZBPI in subjects with confirmed HZ. This analysis involved any subject reporting clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.

End point type	Secondary
----------------	-----------

End point timeframe:

During the entire study period (3 to 5 year period following Day 0)

End point values	GSK1437173A 50-59 YOA Group	GSK1437173A 60-69 YOA Group	GSK1437173A Over 70 YOA Group	GSK1437173A Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	4	3	2	9
Units: Subjects	4	1	2	7

End point values	Placebo 50-59 YOA Group	Placebo 60-69 YOA Group	Placebo Over 70 YOA Group	Placebo Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	103	90	61	254
Units: Subjects	91	74	56	221

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with confirmed HZ episode related mortality

End point title	Number of subjects with confirmed HZ episode related mortality
End point description: The analysis focused on the number of subjects who died due to HZ	
End point type	Secondary
End point timeframe: During the entire study period (3 to 5 year period following Day 0)	

End point values	GSK1437173A 50-59 YOA Group	GSK1437173A 60-69 YOA Group	GSK1437173A Over 70 YOA Group	GSK1437173A Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3491	2140	1709	7340
Units: Subjects	0	0	0	0

End point values	Placebo 50-59 YOA Group	Placebo 60-69 YOA Group	Placebo Over 70 YOA Group	Placebo Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3523	2166	1724	7413
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with HZ related complications

End point title	Number of subjects with HZ related complications
End point description: The analysis focused on the incidence of HZ complications in subjects with confirmed HZ	
End point type	Secondary
End point timeframe: During the entire study period (3 to 5 year period following Day 0)	

End point values	GSK1437173A 50-59 YOA Group	GSK1437173A 60-69 YOA Group	GSK1437173A Over 70 YOA Group	GSK1437173A Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	4	3	2	9
Units: Subjects	0	0	0	0

End point values	Placebo 50-59 YOY Group	Placebo 60-69 YOY Group	Placebo Over 70 YOY Group	Placebo Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	103	90	61	254
Units: Subjects	1	3	2	6

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with confirmed HZ episode related hospitalizations

End point title	Number of subjects with confirmed HZ episode related hospitalizations
End point description: The analysis focused on confirmed HZ episode related hospitalizations.	
End point type	Secondary
End point timeframe: During the entire study period (3 to 5 year period following Day 0)	

End point values	GSK1437173A 50-59 YOA Group	GSK1437173A 60-69 YOA Group	GSK1437173A Over 70 YOA Group	GSK1437173A Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3491	2140	1709	7340
Units: Subjects	0	0	0	0

End point values	Placebo 50-59 YOA Group	Placebo 60-69 YOA Group	Placebo Over 70 YOA Group	Placebo Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3523	2166	1724	7413
Units: Subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with a confirmed HZ episode having a reduction of duration of pain medication associated with HZ

End point title	Number of subjects with a confirmed HZ episode having a reduction of duration of pain medication associated with HZ
End point description:	
The analysis focused on patients who experienced a reduction in duration of pain medication administered for HZ in subjects with confirmed HZ	
End point type	Secondary
End point timeframe:	
During the entire study period (3 to 5 year period following Day 0)	

End point values	GSK1437173A 50-59 YOA Group	GSK1437173A 60-69 YOA Group	GSK1437173A Over 70 YOA Group	GSK1437173A Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	4	3	2	9
Units: Subjects	3	2	1	6

End point values	Placebo 50-59 YOA Group	Placebo 60-69 YOA Group	Placebo Over 70 YOA Group	Placebo Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	103	90	61	254
Units: Subjects	82	63	45	190

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with a confirmed HZ episode taking pain medication associated with HZ

End point title	Number of subjects with a confirmed HZ episode taking pain medication associated with HZ
End point description: The analysis focused on subjects taking pain medication due to HZ	
End point type	Secondary
End point timeframe: During the entire study period (3 to 5 year period following Day 0)	

End point values	GSK1437173A 50-59 YOA Group	GSK1437173A 60-69 YOA Group	GSK1437173A Over 70 YOA Group	GSK1437173A Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	4	3	2	9
Units: Subjects	3	2	1	6

End point values	Placebo 50-59 YOY Group	Placebo 60-69 YOY Group	Placebo Over 70 YOY Group	Placebo Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	103	90	61	254
Units: Subjects	82	63	45	190

Statistical analyses

No statistical analyses for this end point

Secondary: Number of days with severe 'worst' HZ-associated pain

End point title	Number of days with severe 'worst' HZ-associated pain
End point description: Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' ZBPI questionnaire. This Outcome Measure was only assessed participants with confirmed HZ. This analysis involved any subject reporting ZBPI clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.	
End point type	Secondary

End point timeframe:

During the entire study period (3 to 5 year period following Day 0)

End point values	GSK1437173A 50-59 YOA Group	GSK1437173A 60-69 YOA Group	GSK1437173A Over 70 YOA Group	GSK1437173A Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	4	1	2	7
Units: Days				
arithmetic mean (standard deviation)	12 (\pm 11.8)	78 (\pm 0)	9 (\pm 4.2)	20.6 (\pm 26.8)

End point values	Placebo 50-59 YOY Group	Placebo 60-69 YOY Group	Placebo Over 70 YOY Group	Placebo Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	91	74	56	221
Units: Days				
arithmetic mean (standard deviation)	28.7 (\pm 48.4)	21.6 (\pm 29.3)	44 (\pm 74.4)	30.2 (\pm 51.9)

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with confirmed HZ episode related mortality and hospitalizations

End point title	Number of subjects with confirmed HZ episode related mortality and hospitalizations
-----------------	---

End point description:

The analysis focused on confirmed HZ episode related hospitalizations and deaths.

End point type	Secondary
----------------	-----------

End point timeframe:

During the entire study period (3 to 5 year period following Day 0)

End point values	GSK1437173A 50-59 YOA Group	GSK1437173A 60-69 YOA Group	GSK1437173A Over 70 YOA Group	GSK1437173A Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3491	2140	1709	7340
Units: Subjects				
Mortality	0	0	0	0
Hospitalization	0	0	0	0
Mortality or hospitalization	0	0	0	0

End point values	Placebo 50-59 YOA Group	Placebo 60-69 YOA Group	Placebo Over 70 YOA Group	Placebo Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3523	2166	1724	7413
Units: Subjects				
Mortality	0	0	0	0
Hospitalization	0	0	0	0
Mortality or hospitalization	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with HZ related complications, by complication type

End point title	Number of subjects with HZ related complications, by complication type
End point description:	
Complication types included HZ vasculitis, Disseminated Disease, Ophtalmic Disease, Neurologic Disease, Visceral Disease and Stroke. This Outcome Measure was only assessed on participants with confirmed HZ.	
End point type	Secondary
End point timeframe:	
During the entire study period (3 to 5 year period following Day 0)	

End point values	GSK1437173A 50-59 YOA Group	GSK1437173A 60-69 YOA Group	GSK1437173A Over 70 YOA Group	GSK1437173A Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	4	3	2	9
Units: Subjects				
At least one complication	0	0	0	0
HZ vasculitis	0	0	0	0
Disseminated Disease	0	0	0	0
Ophtalmic Disease	0	0	0	0
Neurologic Disease	0	0	0	0
Visceral Disease	0	0	0	0
Stroke	0	0	0	0

End point values	Placebo 50-59 YOA Group	Placebo 60-69 YOA Group	Placebo Over 70 YOA Group	Placebo Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	103	90	61	254

Units: Subjects				
At least one complication	1	3	2	6
HZ vasculitis	0	1	0	1
Disseminated Disease	1	1	2	4
Ophtalmic Disease	0	1	0	1
Neurologic Disease	0	0	0	0
Visceral Disease	0	0	0	0
Stroke	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Secondary: Distribution of pain medication associated with HZ

End point title	Distribution of pain medication associated with HZ
End point description:	The distribution of pain medication included 1 to 3 or more separate medications. This Outcome Measure was only assessed on participants with confirmed HZ.
End point type	Secondary
End point timeframe:	During the entire study period (3 to 5 year period following Day 0)

End point values	GSK1437173A 50-59 YOA Group	GSK1437173A 60-69 YOA Group	GSK1437173A Over 70 YOA Group	GSK1437173A Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	4	3	2	9
Units: Subjects				
At least one pain medication	3	2	1	6
1 pain medication only	1	1	0	2
2 pain medications only	1	1	0	2
3 pain medications or more	1	0	1	2

End point values	Placebo 50-59 YOA Group	Placebo 60-69 YOA Group	Placebo Over 70 YOA Group	Placebo Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	103	90	61	254
Units: Subjects				
At least one pain medication	82	63	45	190
1 pain medication only	30	23	14	67
2 pain medications only	26	19	9	54
3 pain medications or more	26	21	22	69

Statistical analyses

No statistical analyses for this end point

Secondary: Number of days of pain medication associated with HZ

End point title	Number of days of pain medication associated with HZ
-----------------	--

End point description:

The analysis was performed in subjects with a confirmed HZ episode

End point type	Secondary
----------------	-----------

End point timeframe:

During the entire study period (3 to 5 year period following Day 0)

End point values	GSK1437173A 50-59 YOA Group	GSK1437173A 60-69 YOA Group	GSK1437173A Over 70 YOA Group	GSK1437173A Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3	2	1	6
Units: Days				
arithmetic mean (standard deviation)	17.3 (\pm 14.5)	20.5 (\pm 16.3)	63 (\pm 0)	26 (\pm 21.6)

End point values	Placebo 50-59 YOY Group	Placebo 60-69 YOY Group	Placebo Over 70 YOY Group	Placebo Overall Ages Group
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	82	63	45	190
Units: Days				
arithmetic mean (standard deviation)	49.2 (\pm 121.5)	74.3 (\pm 166.3)	127.7 (\pm 266.9)	76.1 (\pm 181.5)

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with any and grade 3 solicited local symptoms

End point title	Number of subjects with any and grade 3 solicited local symptoms
-----------------	--

End point description:

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Significant pain at rest that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

Relationship analysis was not performed.

End point type	Secondary
End point timeframe:	
During the 7-day (Days 0-6) post-vaccination period	

End point values	GSK1437173A Group	Placebo Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4379	4375		
Units: Subjects				
Any Pain, Dose 1 (N=4359,4361)	3120	352		
Grade 3 Pain, Dose 1 (N=4359,4361)	159	6		
Any Redness, Dose 1 (N=4359,4361)	1225	40		
Grade 3 Redness, Dose 1 (N=4359,4361)	82	0		
Any Swelling, Dose 1 (N=4359,4361)	810	31		
Grade 3 Swelling, Dose 1 (N=4359,4361)	28	0		
Any Pain, Dose 2 (N=4207,4224)	2807	258		
Grade 3 Pain, Dose 2 (N=4207,4224)	185	10		
Any Redness, Dose 2 (N=4207,4224)	1151	24		
Grade 3 Redness, Dose 2 (N=4207,4224)	56	0		
Any Swelling, Dose 2 (N=4207,4224)	762	17		
Grade 3 Swelling, Dose 2 (N=4207,4224)	18	0		
Any Pain, Overall (N=4379,4375)	3463	490		
Grade 3 Pain, Overall (N=4379,4375)	293	16		
Any Redness, Overall (N=4379,4375)	1665	59		
Grade 3 Redness, Overall (N=4379,4375)	121	0		
Any Swelling, Overall (N=4379,4375)	1153	46		
Grade 3 Swelling, Overall (N=4379,4375)	43	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with any, grade 3 and related solicited general symptoms

End point title	Number of subjects with any, grade 3 and related solicited general symptoms
-----------------	---

End point description:

Assessed solicited general symptoms were fatigue, GI (gastrointestinal) symptoms (included nausea, vomiting, diarrhoea and/or abdominal pain), fever [defined as oral, axillary, rectal or tympanic temperature equal to or above 37.5 degrees Celsius (°C)], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

End point type	Secondary
End point timeframe:	
Within the 7-day (Days 0-6) post-vaccination period	

End point values	GSK1437173A Group	Placebo Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4372	4376		
Units: Subjects				
Any Fatigue, Dose 1 (N=4346,4362)	1395	531		
Grade 3 Fatigue, Dose 1 (N=4346,4362)	109	29		
Related fatigue, Dose 1 (N=4346,4362)	1153	355		
Any GI symptoms, Dose 1 (N=4346,4362)	465	263		
Grade 3 GI symptoms, Dose 1 (N=4346,4362)	30	12		
Related GI symptoms, Dose 1 (N=4346,4362)	317	141		
Any Headache, Dose 1 (N=4346,4362)	1112	511		
Grade 3 Headache, Dose 1 (N=4346,4362)	67	20		
Related Headache, Dose 1 (N=4346,4362)	891	341		
Any Myalgia, Dose 1 (N=4346,4362)	1446	377		
Grade 3 Myalgia, Dose 1 (N=4346,4362)	104	21		
Related Myalgia, Dose 1 (N=4346,4362)	1231	265		
Any Shivering, Dose 1 (N=4346,4362)	632	166		
Grade 3 Shivering, Dose 1 (N=4346,4362)	69	3		
Related Shivering, Dose 1 (N=4346,4362)	539	104		
Any Temperature, Dose 1 (N=4346,4362)	500	65		
Grade 3 Temperature, Dose 1 (N=4346,4362)	7	1		
Related Temperature, Dose 1 (N=4346,4362)	420	38		
Any Fatigue, Dose 2 (N=4205,4222)	1456	379		
Grade 3 Fatigue, Dose 2 (N=4205,4222)	157	18		
Related fatigue, Dose 2 (N=4205,4222)	1270	279		
Any GI symptoms, Dose 2 (N=4205,4222)	495	183		
Grade 3 GI symptoms, Dose 2 (N=4205,4222)	33	14		
Related GI symptoms, Dose 2 (N=4205,4222)	392	91		
Any Headache, Dose 2 (N=4205,4222)	1249	340		
Grade 3 Headache, Dose 2 (N=4205,4222)	105	13		
Related Headache, Dose 2 (N=4205,4222)	1107	219		
Any Myalgia, Dose 2 (N=4205,4222)	1474	274		
Grade 3 Myalgia, Dose 2 (N=4205,4222)	160	13		

Related Myalgia, Dose 2 (N=4205,4222)	1314	197		
Any Shivering, Dose 2 (N=4205,4222)	947	128		
Grade 3 Shivering, Dose 2 (N=4205,4222)	139	9		
Related Shivering, Dose 2 (N=4205,4222)	838	88		
Any Temperature, Dose 2 (N=4205,4222)	645	72		
Grade 3 Temperature, Dose 2 (N=4205,4222)	8	5		
Related Temperature, Dose 2 (N=4205,4222)	571	40		
Any Fatigue, Overall (N=4372,4376)	2006	728		
Grade 3 Fatigue, Overall (N=4372,4376)	241	46		
Related fatigue, Overall (N=4372,4376)	1724	522		
Any GI symptoms, Overall (N=4372,4376)	787	386		
Grade 3 GI symptoms, Overall (N=4372,4376)	61	25		
Related GI symptoms, Overall (N=4372,4376)	591	206		
Any Headache, Overall (N=4372,4376)	1714	700		
Grade 3 Headache, Overall (N=4372,4376)	157	30		
Related Headache, Overall (N=4372,4376)	1470	469		
Any Myalgia, Overall (N=4372,4376)	2023	529		
Grade 3 Myalgia, Overall (N=4372,4376)	236	31		
Related Myalgia, Overall (N=4372,4376)	1791	390		
Any Shivering, Overall (N=4372,4376)	1232	259		
Grade 3 Shivering, Overall (N=4372,4376)	192	11		
Related Shivering, Overall (N=4372,4376)	1082	177		
Any Temperature, Overall (N=4372,4376)	940	132		
Grade 3 Temperature, Overall (N=4372,4376)	14	6		
Related Temperature, Overall (N=4372,4376)	813	78		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with any and Grade 3 symptoms (solicited and unsolicited)

End point title	Number of subjects with any and Grade 3 symptoms (solicited and unsolicited)
End point description: Number of subjects with any and grade 3 solicited and unsolicited symptoms were tabulated.	
End point type	Secondary

End point timeframe:

Within the 7-day (Days 0-6) post-vaccination period

End point values	GSK1437173A Group	Placebo Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4457	4464		
Units: Subjects				
Any solicited or unsolicited symptoms	3766	1691		
Grade 3 solicited or unsolicited symptoms	759	145		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with any and related potential Immune mediated diseases (pIMDs)

End point title	Number of subjects with any and related potential Immune mediated diseases (pIMDs)
-----------------	--

End point description:

Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) in all subjects

End point type	Secondary
----------------	-----------

End point timeframe:

During the entire study period (3 to 5 year period following Day 0)

End point values	GSK1437173A Group	Placebo Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7695	7710		
Units: Subjects				
Any pIMDs	87	105		
Related pIMDs	8	12		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with AEs with any and related medically attended visit (MAEs)

End point title	Number of subjects with AEs with any and related medically attended visit (MAEs)
-----------------	--

End point description:

Occurrence and relationship to vaccination of medically attended visits (defined as hospitalizations, emergency room visits or visits to or from medical personnel), other than routine health care visits in all subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

From Month 0 to Month 8 post-vaccination

End point values	GSK1437173A Group	Placebo Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7695	7710		
Units: Subjects				
Any MAEs	2952	3072		
Related MAEs	142	60		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with unsolicited adverse events (AEs)

End point title	Number of subjects with unsolicited adverse events (AEs)
-----------------	--

End point description:

Occurrence, intensity and relationship to vaccination of unsolicited AEs, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects. An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

Within 30 days (Days 0 - 29) after each vaccination

End point values	GSK1437173A Group	Placebo Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7695	7710		
Units: Subjects				
Any AEs	3534	2426		
Grade 3 AEs	609	298		
Related AEs	2199	439		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with serious adverse events (SAEs)

End point title	Number of subjects with serious adverse events (SAEs)
-----------------	---

End point description:

Occurrence and relationship to vaccination of all SAEs in all subjects. Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

End point type	Secondary
----------------	-----------

End point timeframe:

Within the 30-day (Days 0-29) post-vaccination period, up to Month 14 and up to study end (3 to 5 year period following Day 0)

End point values	GSK1437173A Group	Placebo Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7695	7710		
Units: Subjects				
Any SAEs (up to Day 30)	88	97		
Related SAEs (up to Day 30)	1	3		
Any SAEs (up to Month 14)	594	590		
Related SAEs (up to Month 14)	3	6		
Any SAEs (up to study end)	727	731		
Related SAEs (up to study end)	3	7		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with SAEs related to study participation or to a concurrent GSK medication/vaccine

End point title	Number of subjects with SAEs related to study participation or to a concurrent GSK medication/vaccine
-----------------	---

End point description:

The number of subjects with SAEs related to study participation or to a concurrent GSK medication/vaccine were tabulated.

End point type	Secondary
----------------	-----------

End point timeframe:

During the entire study period (3 to 5 year period following Day 0).

End point values	GSK1437173A Group	Placebo Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7695	7710		
Units: Subjects	43	25		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with fatal SAEs

End point title	Number of subjects with fatal SAEs
End point description:	
Number of subjects with fatal SAEs during the entire study period were tabulated.	
End point type	Secondary
End point timeframe:	
During the entire study period (3 to 5 years following day 0).	

End point values	GSK1437173A Group	Placebo Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7695	7710		
Units: Subjects	208	221		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Solicited symptoms: within 7 days post-vaccination Unsolicited AEs: within 30 days post vaccination
SAEs: during the entire study period (3 to 5 year period following Day 0)

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	10.0
--------------------	------

Reporting groups

Reporting group title	GSK1437173A Group
-----------------------	-------------------

Reporting group description:

Subjects received herpes zoster subunit vaccine (gE/AS01B vaccine: GSK1437173A) according to a 0, 2-month schedule.

Reporting group title	Placebo Group
-----------------------	---------------

Reporting group description:

Subjects received saline solution (NaCl solution) as control according to a 0, 2-month schedule.

Serious adverse events	GSK1437173A Group	Placebo Group	
Total subjects affected by serious adverse events			
subjects affected / exposed	727 / 7695 (9.45%)	731 / 7710 (9.48%)	
number of deaths (all causes)	11	15	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Abdominal neoplasm			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Acute leukaemia			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Acute myeloid leukaemia			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Acute promyelocytic leukaemia			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma pancreas			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Adenocarcinoma gastric			
subjects affected / exposed	2 / 7695 (0.03%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Adenocarcinoma of colon			
subjects affected / exposed	2 / 7695 (0.03%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Angioimmunoblastic t-cell lymphoma			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	4 / 7695 (0.05%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adult t-cell lymphoma/leukaemia			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Benign neoplasm of thyroid gland			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of bladder			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of orbit			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign renal neoplasm			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct adenocarcinoma			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign soft tissue neoplasm			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct cancer			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Bladder cancer			
subjects affected / exposed	3 / 7695 (0.04%)	5 / 7710 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 1	
Bladder neoplasm			

subjects affected / exposed	0 / 7695 (0.00%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Brain neoplasm			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Bowen's disease			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain cancer metastatic			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Breast cancer			
subjects affected / exposed	8 / 7695 (0.10%)	6 / 7710 (0.08%)	
occurrences causally related to treatment / all	0 / 8	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 1	
Breast cancer female			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain neoplasm malignant			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Breast cancer in situ			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer metastatic			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Bronchial carcinoma			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 2	
Bronchial neoplasm			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cervix carcinoma recurrent			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carcinoid tumour of the small bowel			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervix carcinoma			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic myeloid leukaemia			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic lymphocytic leukaemia			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangiocarcinoma			

subjects affected / exposed	3 / 7695 (0.04%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 3	
Colon adenoma			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer			
subjects affected / exposed	7 / 7695 (0.09%)	11 / 7710 (0.14%)	
occurrences causally related to treatment / all	0 / 7	0 / 11	
deaths causally related to treatment / all	0 / 2	0 / 5	
Diffuse large b-cell lymphoma			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Endometrial adenocarcinoma			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extranodal marginal zone b-cell lymphoma (malt type)			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fallopian tube cancer			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder cancer			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Gastrointestinal neoplasm			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gastric cancer			
subjects affected / exposed	4 / 7695 (0.05%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 3	0 / 1	
Glioblastoma			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Glioblastoma multiforme			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gastrointestinal stromal tumour			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glioma			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Glomus tumour			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cancer metastatic			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hepatic cancer			

subjects affected / exposed	4 / 7695 (0.05%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 3	0 / 1	
Hepatic neoplasm			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatocellular carcinoma			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 2	
Hypopharyngeal cancer			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Intraductal proliferative breast lesion			
subjects affected / exposed	3 / 7695 (0.04%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Invasive ductal breast carcinoma			
subjects affected / exposed	5 / 7695 (0.06%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal cancer			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Invasive papillary breast carcinoma			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal neoplasm			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Leukaemia			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Lip and/or oral cavity cancer			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lip squamous cell carcinoma			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lipoma			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma			
subjects affected / exposed	4 / 7695 (0.05%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 2	
Lung adenocarcinoma metastatic			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Lung adenocarcinoma stage i			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm malignant			

subjects affected / exposed	11 / 7695 (0.14%)	6 / 7710 (0.08%)	
occurrences causally related to treatment / all	0 / 11	0 / 6	
deaths causally related to treatment / all	0 / 9	0 / 3	
Lung neoplasm			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lung cancer metastatic			
subjects affected / exposed	3 / 7695 (0.04%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 1	
Lymphoma			
subjects affected / exposed	1 / 7695 (0.01%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 3	
Malignant melanoma			
subjects affected / exposed	2 / 7695 (0.03%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm of pleura metastatic			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Malignant neoplasm of unknown primary site			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Melanocytic naevus			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma benign			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant pleural effusion			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to liver			
subjects affected / exposed	3 / 7695 (0.04%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 2	
Metastases to lung			
subjects affected / exposed	1 / 7695 (0.01%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 2	
Metastases to central nervous system			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastases to lymph			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to peritoneum			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Metastases to pleura			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastasis			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metastatic carcinoma of the bladder			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastatic malignant melanoma			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastatic squamous cell carcinoma			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastatic neoplasm			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Nasopharyngeal cancer			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm malignant			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Neoplasm skin			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal carcinoma			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Oesophageal adenocarcinoma			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Non-small cell lung cancer			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Neuroendocrine carcinoma			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Ovarian fibroma			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cancer			
subjects affected / exposed	3 / 7695 (0.04%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Oesophageal squamous cell carcinoma			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic carcinoma			
subjects affected / exposed	6 / 7695 (0.08%)	8 / 7710 (0.10%)	
occurrences causally related to treatment / all	0 / 6	0 / 9	
deaths causally related to treatment / all	0 / 5	0 / 8	
Pancreatic carcinoma metastatic			

subjects affected / exposed	3 / 7695 (0.04%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 3	0 / 1	
Pancreatic neoplasm			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian neoplasm			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Phaeochromocytoma			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasma cell myeloma			
subjects affected / exposed	3 / 7695 (0.04%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 0	
Pleural mesothelioma			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Prostate cancer recurrent			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Prostate cancer metastatic			
subjects affected / exposed	3 / 7695 (0.04%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 3	0 / 0	
Prostate cancer			

subjects affected / exposed	7 / 7695 (0.09%)	9 / 7710 (0.12%)	
occurrences causally related to treatment / all	0 / 7	0 / 9	
deaths causally related to treatment / all	0 / 1	0 / 0	
Prostatic adenoma			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal adenocarcinoma			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Rectal adenoma			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal cancer			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Renal cancer			
subjects affected / exposed	1 / 7695 (0.01%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cancer metastatic			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Renal neoplasm			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal oncocytoma			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin cancer			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Small intestine adenocarcinoma			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Spinal cord neoplasm			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of lung			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Squamous cell carcinoma			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of skin			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the oral cavity			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 9	0 / 1	
Thyroid adenoma			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid cancer			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Testicular neoplasm			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid neoplasm			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tongue neoplasm malignant stage unspecified			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Tumour haemorrhage			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine cancer			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Uterine leiomyoma			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval cancer			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Vascular disorders			
Aneurysm			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiodysplasia			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic dilatation			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic aneurysm			
subjects affected / exposed	0 / 7695 (0.00%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic dissection			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic rupture			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Aortic stenosis			
subjects affected / exposed	0 / 7695 (0.00%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial thrombosis			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial disorder			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Circulatory collapse			
subjects affected / exposed	2 / 7695 (0.03%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 2	0 / 2	
Arteriosclerosis			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bleeding varicose vein			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	3 / 7695 (0.04%)	5 / 7710 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Diabetic vascular disorder			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Essential hypertension			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			

subjects affected / exposed	8 / 7695 (0.10%)	10 / 7710 (0.13%)	
occurrences causally related to treatment / all	0 / 8	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 1	
Haemorrhage			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			
subjects affected / exposed	1 / 7695 (0.01%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemodynamic instability			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hypertensive emergency			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	2 / 7695 (0.03%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
subjects affected / exposed	2 / 7695 (0.03%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypertension			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemic shock			

subjects affected / exposed	0 / 7695 (0.00%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 3	
Intermittent claudication			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stenosis			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			
subjects affected / exposed	2 / 7695 (0.03%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Orthostatic hypotension			
subjects affected / exposed	2 / 7695 (0.03%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery thrombosis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral embolism			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral vascular disorder			

subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Superior vena cava syndrome			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Shock haemorrhagic			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral venous disease			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyarteritis nodosa			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose vein			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose ulceration			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Temporal arteritis			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Cardiac pacemaker replacement			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	3 / 7695 (0.04%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Chest discomfort			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	12 / 7695 (0.16%)	10 / 7710 (0.13%)	
occurrences causally related to treatment / all	0 / 12	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	11 / 7695 (0.14%)	15 / 7710 (0.19%)	
occurrences causally related to treatment / all	0 / 11	0 / 15	
deaths causally related to treatment / all	0 / 11	0 / 15	
Device dislocation			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device failure			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	

Drowning			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Drug withdrawal syndrome			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gravitational oedema			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hernia			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired healing			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza like illness			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaise			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multi-organ failure			

subjects affected / exposed	6 / 7695 (0.08%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 6	0 / 2	
Non-cardiac chest pain			
subjects affected / exposed	2 / 7695 (0.03%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral swelling			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyp			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	2 / 7695 (0.03%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Strangulated hernia			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden death			
subjects affected / exposed	5 / 7695 (0.06%)	7 / 7710 (0.09%)	
occurrences causally related to treatment / all	0 / 5	0 / 7	
deaths causally related to treatment / all	0 / 5	0 / 7	
Sudden cardiac death			

subjects affected / exposed	0 / 7695 (0.00%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 3	
Systemic inflammatory response syndrome			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug hypersensitivity			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypersensitivity			
subjects affected / exposed	2 / 7695 (0.03%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sarcoidosis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	3 / 7695 (0.04%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystocele			
subjects affected / exposed	3 / 7695 (0.04%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Endometrial hypertrophy			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibrocystic breast disease			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cyst			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postmenopausal haemorrhage			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatitis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatomegaly			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectocele			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine enlargement			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine prolapse			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterovaginal prolapse			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	3 / 7695 (0.04%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	2 / 7695 (0.03%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 2	0 / 2	
Acute pulmonary oedema			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Aspiration			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Bronchitis chronic			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Bronchiectasis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma			

subjects affected / exposed	6 / 7695 (0.08%)	5 / 7710 (0.06%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 1	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	8 / 7695 (0.10%)	8 / 7710 (0.10%)	
occurrences causally related to treatment / all	0 / 9	0 / 10	
deaths causally related to treatment / all	0 / 1	0 / 4	
Emphysema			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Epistaxis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Idiopathic pulmonary fibrosis			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung disorder			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Nasal polyps			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paranasal cyst			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal turbinate hypertrophy			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal septum deviation			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleurisy			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	3 / 7695 (0.04%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 1	
Pleural calcification			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pickwickian syndrome			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			

subjects affected / exposed	1 / 7695 (0.01%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 3	
Pneumothorax			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary bulla			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary congestion			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	6 / 7695 (0.08%)	13 / 7710 (0.17%)	
occurrences causally related to treatment / all	0 / 6	0 / 13	
deaths causally related to treatment / all	0 / 4	0 / 4	
Pulmonary fibrosis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory arrest			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pulmonary oedema			
subjects affected / exposed	2 / 7695 (0.03%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Respiratory acidosis			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Respiratory failure			
subjects affected / exposed	7 / 7695 (0.09%)	12 / 7710 (0.16%)	
occurrences causally related to treatment / all	0 / 7	0 / 12	
deaths causally related to treatment / all	0 / 5	0 / 8	
Sleep apnoea syndrome			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory distress			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Psychiatric disorders			
Abnormal behaviour			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Completed suicide			
subjects affected / exposed	4 / 7695 (0.05%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 4	0 / 4	
Delirium			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adjustment disorder			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delirium febrile			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Generalised anxiety disorder			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Korsakoff's syndrome			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Major depression			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	3 / 7695 (0.04%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Suicidal ideation			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Somatoform disorder			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychotic disorder			
subjects affected / exposed	1 / 7695 (0.01%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			
subjects affected / exposed	4 / 7695 (0.05%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Blood heavy metal increased			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoglobin decreased			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anticoagulation drug level above therapeutic			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Accident			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Acetabulum fracture			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anastomotic leak			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Aneurysm perforation			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Burns second degree			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankle fracture			
subjects affected / exposed	7 / 7695 (0.09%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burns third degree			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract operation complication			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chemical poisoning			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest injury			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Comminuted fracture			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clavicle fracture			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Concussion			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Electrical burn			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial bones fracture			
subjects affected / exposed	2 / 7695 (0.03%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye penetration			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral neck fracture			
subjects affected / exposed	5 / 7695 (0.06%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			

subjects affected / exposed	2 / 7695 (0.03%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Femur fracture			
subjects affected / exposed	7 / 7695 (0.09%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibula fracture			
subjects affected / exposed	3 / 7695 (0.04%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Flail chest			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot fracture			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gun shot wound			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Fractured sacrum			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Forearm fracture			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hand fracture			

subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Head injury			
subjects affected / exposed	3 / 7695 (0.04%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hip fracture			
subjects affected / exposed	2 / 7695 (0.03%)	6 / 7710 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated incisional hernia			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	2 / 7695 (0.03%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incisional hernia			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint injury			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laceration			
subjects affected / exposed	1 / 7695 (0.01%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Joint dislocation			

subjects affected / exposed	3 / 7695 (0.04%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament rupture			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb injury			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower limb fracture			
subjects affected / exposed	1 / 7695 (0.01%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament sprain			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple fractures			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus injury			
subjects affected / exposed	3 / 7695 (0.04%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle rupture			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle strain			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple injuries			
subjects affected / exposed	1 / 7695 (0.01%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Overdose			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Open fracture			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nerve root injury cervical			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patella fracture			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax traumatic			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic fracture			

subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Poisoning			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural pain			
subjects affected / exposed	3 / 7695 (0.04%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radius fracture			
subjects affected / exposed	7 / 7695 (0.09%)	7 / 7710 (0.09%)	
occurrences causally related to treatment / all	0 / 7	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory fume inhalation disorder			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pubis fracture			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			
subjects affected / exposed	3 / 7695 (0.04%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			

subjects affected / exposed	1 / 7695 (0.01%)	5 / 7710 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 3	
Seroma			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Snake bite			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull fracture			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Skin abrasion			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture			
subjects affected / exposed	2 / 7695 (0.03%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord injury			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Soft tissue injury			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fracture			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic rupture			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Sternal fracture			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	2 / 7695 (0.03%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Spinal cord injury cervical			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Subdural haemorrhage			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Tibia fracture			
subjects affected / exposed	3 / 7695 (0.04%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon rupture			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon injury			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	3 / 7695 (0.04%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Traumatic intracranial haemorrhage			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Traumatic shock			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Upper limb fracture			
subjects affected / exposed	4 / 7695 (0.05%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulna fracture			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular pseudoaneurysm ruptured			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound dehiscence			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wrist fracture			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Cystic fibrosis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hernia congenital			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocele			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	4 / 7695 (0.05%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina pectoris			
subjects affected / exposed	3 / 7695 (0.04%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			
subjects affected / exposed	8 / 7695 (0.10%)	19 / 7710 (0.25%)	
occurrences causally related to treatment / all	0 / 8	0 / 19	
deaths causally related to treatment / all	0 / 3	0 / 10	

Angina unstable			
subjects affected / exposed	2 / 7695 (0.03%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve disease			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve stenosis			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia			
subjects affected / exposed	6 / 7695 (0.08%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 6	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Atrial fibrillation			
subjects affected / exposed	19 / 7695 (0.25%)	6 / 7710 (0.08%)	
occurrences causally related to treatment / all	0 / 23	0 / 6	
deaths causally related to treatment / all	0 / 2	0 / 0	
Atrial flutter			
subjects affected / exposed	4 / 7695 (0.05%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Atrial tachycardia			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Atrioventricular block second degree			

subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block complete			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			
subjects affected / exposed	2 / 7695 (0.03%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradyarrhythmia			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	8 / 7695 (0.10%)	8 / 7710 (0.10%)	
occurrences causally related to treatment / all	0 / 8	0 / 8	
deaths causally related to treatment / all	0 / 7	0 / 6	
Cardiac failure			
subjects affected / exposed	20 / 7695 (0.26%)	24 / 7710 (0.31%)	
occurrences causally related to treatment / all	0 / 21	0 / 27	
deaths causally related to treatment / all	0 / 11	0 / 15	
Cardiac failure acute			
subjects affected / exposed	0 / 7695 (0.00%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 2	
Cardiac failure congestive			
subjects affected / exposed	14 / 7695 (0.18%)	10 / 7710 (0.13%)	
occurrences causally related to treatment / all	0 / 15	0 / 10	
deaths causally related to treatment / all	0 / 2	0 / 3	
Cardiac failure chronic			

subjects affected / exposed	2 / 7695 (0.03%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cardiac valve disease			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiogenic shock			
subjects affected / exposed	3 / 7695 (0.04%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardio-respiratory arrest			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Cardiomyopathy alcoholic			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cardiopulmonary failure			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cardiovascular deconditioning			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiovascular insufficiency			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cor pulmonale			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery insufficiency			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Coronary artery disease			
subjects affected / exposed	11 / 7695 (0.14%)	17 / 7710 (0.22%)	
occurrences causally related to treatment / all	0 / 11	0 / 19	
deaths causally related to treatment / all	0 / 1	0 / 2	
Coronary artery occlusion			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery stenosis			
subjects affected / exposed	4 / 7695 (0.05%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracardiac thrombus			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve prolapse			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular failure			
subjects affected / exposed	3 / 7695 (0.04%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Mitral valve stenosis			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	28 / 7695 (0.36%)	27 / 7710 (0.35%)	
occurrences causally related to treatment / all	0 / 28	0 / 27	
deaths causally related to treatment / all	0 / 15	0 / 13	
Myocardial ischaemia			
subjects affected / exposed	7 / 7695 (0.09%)	11 / 7710 (0.14%)	
occurrences causally related to treatment / all	0 / 7	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 4	
Palpitations			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pericarditis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Right ventricular failure			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus node dysfunction			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress cardiomyopathy			

subjects affected / exposed	2 / 7695 (0.03%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachycardia			
subjects affected / exposed	3 / 7695 (0.04%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular extrasystoles			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular fibrillation			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Ventricular tachycardia			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertrophic cardiomyopathy			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Odontogenic cyst			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Aphasia			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal ganglia haemorrhage			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amyotrophic lateral sclerosis			
subjects affected / exposed	2 / 7695 (0.03%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Basal ganglia infarction			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain injury			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery disease			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery thrombosis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery stenosis			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haemorrhage			

subjects affected / exposed	2 / 7695 (0.03%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 4	
Cerebral infarction			
subjects affected / exposed	8 / 7695 (0.10%)	6 / 7710 (0.08%)	
occurrences causally related to treatment / all	0 / 8	0 / 7	
deaths causally related to treatment / all	0 / 4	0 / 3	
Cerebral ischaemia			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cerebrovascular accident			
subjects affected / exposed	19 / 7695 (0.25%)	12 / 7710 (0.16%)	
occurrences causally related to treatment / all	0 / 19	0 / 12	
deaths causally related to treatment / all	0 / 8	0 / 6	
Cerebrovascular disorder			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular insufficiency			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cervicobrachial syndrome			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic inflammatory demyelinating polyradiculoneuropathy			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia alzheimer's type			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Coma			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Demyelinating polyneuropathy			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	3 / 7695 (0.04%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic neuropathy			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalopathy			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epilepsy			
subjects affected / exposed	1 / 7695 (0.01%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Generalised tonic-clonic seizure			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Guillain-barre syndrome			

subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage intracranial			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Haemorrhagic transformation stroke			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	4 / 7695 (0.05%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiparesis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoaesthesia			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocephalus			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial aneurysm			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic stroke			

subjects affected / exposed	1 / 7695 (0.01%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ivth nerve paralysis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lacunar infarction			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar radiculopathy			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Migraine			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic encephalopathy			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Mononeuritis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myasthenia gravis			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelopathy			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nerve compression			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorder			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuritis cranial			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraneoplastic neurological syndrome			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraesthesia			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post polio syndrome			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sciatica			
subjects affected / exposed	2 / 7695 (0.03%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiculopathy			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reversible ischaemic neurological deficit			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ruptured cerebral aneurysm			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Spinal claudication			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage			
subjects affected / exposed	2 / 7695 (0.03%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 1	
Syncope			
subjects affected / exposed	8 / 7695 (0.10%)	8 / 7710 (0.10%)	
occurrences causally related to treatment / all	0 / 8	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			

subjects affected / exposed	3 / 7695 (0.04%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	8 / 7695 (0.10%)	6 / 7710 (0.08%)	
occurrences causally related to treatment / all	0 / 8	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Trigeminal neuralgia			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient global amnesia			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vasculitis cerebral			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular encephalopathy			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viith nerve paralysis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	6 / 7695 (0.08%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Disseminated intravascular coagulation			

subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Anaemia vitamin b12 deficiency			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heparin-induced thrombocytopenia			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic anaemia			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypochromic anaemia			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron deficiency anaemia			
subjects affected / exposed	2 / 7695 (0.03%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune thrombocytopenic purpura			
subjects affected / exposed	3 / 7695 (0.04%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	1 / 3	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy mediastinal			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic haemorrhage			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic infarction			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Motion sickness			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deafness neurosensory			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo			
subjects affected / exposed	4 / 7695 (0.05%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo positional			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			

Amaurosis fugax			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eyelid ptosis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract			
subjects affected / exposed	2 / 7695 (0.03%)	5 / 7710 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lens dislocation			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glaucoma			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular cyst			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular hole			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neovascular age-related macular degeneration			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal artery occlusion			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal tear			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal detachment			
subjects affected / exposed	1 / 7695 (0.01%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous detachment			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous haemorrhage			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal hernia			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	2 / 7695 (0.03%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal strangulated hernia			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Colitis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ischaemic			
subjects affected / exposed	1 / 7695 (0.01%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Crohn's disease			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum			
subjects affected / exposed	3 / 7695 (0.04%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	4 / 7695 (0.05%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Diverticulum intestinal			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal perforation			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenitis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterovesical fistula			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Functional gastrointestinal disorder			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric haemorrhage			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric mucosal lesion			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric polyps			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer			
subjects affected / exposed	3 / 7695 (0.04%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer haemorrhage			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	5 / 7695 (0.06%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis alcoholic			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal angiodysplasia			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	3 / 7695 (0.04%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 2	
Gastrointestinal polyp haemorrhage			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gingival disorder			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids			
subjects affected / exposed	1 / 7695 (0.01%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hiatus hernia			
subjects affected / exposed	0 / 7695 (0.00%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	1 / 7695 (0.01%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Inguinal hernia			
subjects affected / exposed	3 / 7695 (0.04%)	8 / 7710 (0.10%)	
occurrences causally related to treatment / all	0 / 3	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated umbilical hernia			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal congestion			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	3 / 7695 (0.04%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Intestinal polyp			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Irritable bowel syndrome			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine polyp			
subjects affected / exposed	1 / 7695 (0.01%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mallory-weiss syndrome			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melaena			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Oesophageal ulcer			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Oesophagitis			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal varices haemorrhage			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pancreatic fistula			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic cyst			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	4 / 7695 (0.05%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	5 / 7695 (0.06%)	6 / 7710 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pancreatitis necrotising			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peptic ulcer			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periodontal disease			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peptic ulcer perforation			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritoneal cyst			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritoneal haemorrhage			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumoperitoneum			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Portal hypertensive gastropathy			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal polyp			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal haemorrhage			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	2 / 7695 (0.03%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic artery aneurysm			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subileus			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis mesenteric vessel			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	2 / 7695 (0.03%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Volvulus			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Vomiting			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Bile duct obstruction			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct stenosis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct stone			
subjects affected / exposed	0 / 7695 (0.00%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary colic			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			
subjects affected / exposed	5 / 7695 (0.06%)	6 / 7710 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis acute			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	7 / 7695 (0.09%)	10 / 7710 (0.13%)	
occurrences causally related to treatment / all	0 / 7	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			
subjects affected / exposed	6 / 7695 (0.08%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatty liver alcoholic			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gallbladder polyp			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic failure			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Hepatic cirrhosis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hepatotoxicity			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice cholestatic			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary dyskinesia			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Decubitus ulcer			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eczema			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermal cyst			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erythema multiforme			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukoplakia			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriasis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkeratosis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin ulcer			
subjects affected / exposed	4 / 7695 (0.05%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Azotaemia			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Acute kidney injury			
subjects affected / exposed	8 / 7695 (0.10%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 8	0 / 4	
deaths causally related to treatment / all	0 / 6	0 / 1	
Bladder prolapse			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus urinary			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic kidney disease			

subjects affected / exposed	2 / 7695 (0.03%)	6 / 7710 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 1	0 / 4	
Calculus bladder			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus ureteric			
subjects affected / exposed	4 / 7695 (0.05%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic nephropathy			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery arteriosclerosis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cyst			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal colic			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery occlusion			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	0 / 7695 (0.00%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 2	
Renal impairment			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tubulointerstitial nephritis			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress urinary incontinence			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral polyp			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary incontinence			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			

subjects affected / exposed	1 / 7695 (0.01%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Goitre			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basedow's disease			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypopituitarism			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroiditis subacute			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthropathy			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	2 / 7695 (0.03%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Costochondritis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fasciitis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Intervertebral disc degeneration			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot deformity			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	1 / 7695 (0.01%)	7 / 7710 (0.09%)	
occurrences causally related to treatment / all	0 / 1	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint destruction			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc disorder			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar spinal stenosis			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle spasms			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal pain			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myalgia			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck pain			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteochondrosis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	8 / 7695 (0.10%)	11 / 7710 (0.14%)	
occurrences causally related to treatment / all	0 / 8	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteitis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteolysis			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periarthritis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyarthritis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteonecrosis			
subjects affected / exposed	4 / 7695 (0.05%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polymyalgia rheumatica			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyolysis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatoid arthritis			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotator cuff syndrome			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue mass			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal osteoarthritis			
subjects affected / exposed	1 / 7695 (0.01%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal column stenosis			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal disorder			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Synovial cyst			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Still's disease adult onset			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylolisthesis			
subjects affected / exposed	3 / 7695 (0.04%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendonitis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Systemic lupus erythematosus			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abdominal infection			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal sepsis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Abscess neck			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal abscess			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendiceal abscess			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis perforated			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			

subjects affected / exposed	3 / 7695 (0.04%)	6 / 7710 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atypical pneumonia			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteriuria			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial infection			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Breast abscess			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary sepsis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis bacterial			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			

subjects affected / exposed	3 / 7695 (0.04%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Candiduria			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchopneumonia			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Catheter site infection			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	8 / 7695 (0.10%)	6 / 7710 (0.08%)	
occurrences causally related to treatment / all	0 / 8	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis orbital			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis streptococcal			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic sinusitis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			

subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			
subjects affected / exposed	0 / 7695 (0.00%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 2	
Dengue fever			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis klebsiella			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic gangrene			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	4 / 7695 (0.05%)	6 / 7710 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 2	
Encephalomyelitis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis			

subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Endometritis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
subjects affected / exposed	2 / 7695 (0.03%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fungaemia			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gangrene			
subjects affected / exposed	3 / 7695 (0.04%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis caliciviral			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	3 / 7695 (0.04%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gastroenteritis salmonella			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis clostridial			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal infection			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Helicobacter gastritis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis a			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected skin ulcer			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Infected dermal cyst			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infectious colitis			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Klebsiella sepsis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Labyrinthitis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leptospirosis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lobar pneumonia			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver abscess			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			

subjects affected / exposed	1 / 7695 (0.01%)	6 / 7710 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 6	
deaths causally related to treatment / all	0 / 1	0 / 1	
Localised infection			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymph node tuberculosis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infection			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Meningitis pneumococcal			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal abscess			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mycobacterial infection			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Neuroborreliosis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasopharyngitis			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Osteomyelitis			
subjects affected / exposed	4 / 7695 (0.05%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis chronic			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Otitis media chronic			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periodontitis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonsillar abscess			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pertussis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngotonsillitis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pneumonia			
subjects affected / exposed	40 / 7695 (0.52%)	26 / 7710 (0.34%)	
occurrences causally related to treatment / all	0 / 41	0 / 28	
deaths causally related to treatment / all	0 / 15	0 / 9	
Pneumonia bacterial			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pneumonia mycoplasmal			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia pneumococcal			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural infection			
subjects affected / exposed	0 / 7695 (0.00%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudomembranous colitis			
subjects affected / exposed	2 / 7695 (0.03%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pyelonephritis acute			

subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	3 / 7695 (0.04%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	6 / 7695 (0.08%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Sepsis			
subjects affected / exposed	7 / 7695 (0.09%)	13 / 7710 (0.17%)	
occurrences causally related to treatment / all	0 / 7	0 / 14	
deaths causally related to treatment / all	0 / 5	0 / 9	
Septic shock			
subjects affected / exposed	1 / 7695 (0.01%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 2	
Shigella infection			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinusitis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Serratia infection			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Sinusitis fungal			

subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue infection			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Subcutaneous abscess			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdiaphragmatic abscess			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal infection			
subjects affected / exposed	2 / 7695 (0.03%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Superinfection			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Testicular abscess			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic shock syndrome			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Tularaemia			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheobronchitis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection bacterial			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethritis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	2 / 7695 (0.03%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	2 / 7695 (0.03%)	3 / 7710 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Urinary tract infection			
subjects affected / exposed	10 / 7695 (0.13%)	10 / 7710 (0.13%)	
occurrences causally related to treatment / all	0 / 10	0 / 10	
deaths causally related to treatment / all	0 / 2	0 / 1	
Vestibular neuronitis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral upper respiratory tract infection			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral sepsis			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Visceral leishmaniasis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			
subjects affected / exposed	2 / 7695 (0.03%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection pseudomonas			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Wound infection staphylococcal			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	4 / 7695 (0.05%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Diabetes mellitus			

subjects affected / exposed	3 / 7695 (0.04%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrolyte imbalance			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Diabetes mellitus inadequate control			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			
subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperammonaemia			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	1 / 7695 (0.01%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gout			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	1 / 7695 (0.01%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hypertriglyceridaemia			

subjects affected / exposed	1 / 7695 (0.01%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperlipidaemia			
subjects affected / exposed	3 / 7695 (0.04%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	2 / 7695 (0.03%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			
subjects affected / exposed	3 / 7695 (0.04%)	0 / 7710 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ketoacidosis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malnutrition			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	2 / 7695 (0.03%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 1 diabetes mellitus			
subjects affected / exposed	0 / 7695 (0.00%)	2 / 7710 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obesity			

subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic acidosis			
subjects affected / exposed	0 / 7695 (0.00%)	1 / 7710 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Type 2 diabetes mellitus			
subjects affected / exposed	2 / 7695 (0.03%)	4 / 7710 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	GSK1437173A Group	Placebo Group	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5586 / 7695 (72.59%)	1893 / 7710 (24.55%)	
Nervous system disorders			
Headache			
subjects affected / exposed	2167 / 7695 (28.16%)	929 / 7710 (12.05%)	
occurrences (all)	3044	1198	
General disorders and administration site conditions			
Chills			
subjects affected / exposed	1464 / 7695 (19.03%)	276 / 7710 (3.58%)	
occurrences (all)	1860	314	
Injection site erythema			
subjects affected / exposed	493 / 7695 (6.41%)	10 / 7710 (0.13%)	
occurrences (all)	636	11	
Fatigue			
subjects affected / exposed	2211 / 7695 (28.73%)	770 / 7710 (9.99%)	
occurrences (all)	3111	961	
Injection site pain			

subjects affected / exposed	1390 / 7695 (18.06%)	104 / 7710 (1.35%)	
occurrences (all)	2090	118	
Injection site swelling			
subjects affected / exposed	401 / 7695 (5.21%)	6 / 7710 (0.08%)	
occurrences (all)	515	6	
Swelling			
subjects affected / exposed	1154 / 7695 (15.00%)	46 / 7710 (0.60%)	
occurrences (all)	1573	48	
Pyrexia			
subjects affected / exposed	1498 / 7695 (19.47%)	168 / 7710 (2.18%)	
occurrences (all)	1839	176	
Pain			
subjects affected / exposed	3575 / 7695 (46.46%)	505 / 7710 (6.55%)	
occurrences (all)	6064	627	
Gastrointestinal disorders			
Gastrointestinal disorder			
subjects affected / exposed	792 / 7695 (10.29%)	389 / 7710 (5.05%)	
occurrences (all)	967	449	
Skin and subcutaneous tissue disorders			
Erythema			
subjects affected / exposed	1690 / 7695 (21.96%)	69 / 7710 (0.89%)	
occurrences (all)	2408	75	
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	2277 / 7695 (29.59%)	571 / 7710 (7.41%)	
occurrences (all)	3234	704	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
18 April 2014	<p>It is predicted that study ZOSTER-006 will reach the conditions required for triggering final analysis of herpes zoster (HZ) primary endpoint about one year before those conditions being reached for study ZOSTER-022. Therefore GSK decided, as originally planned in these circumstances, to dissociate the two studies in terms of timing of the analysis of each study. Moreover, a two-step approach is allowed for the analysis of each study. Both studies will end concurrently .</p> <p>In study ZOSTER-022, postherpetic neuralgia (PHN) is demoted from co-primary endpoint to a descriptive secondary endpoint and the overall PHN co-primary endpoint in subjects ≥ 70 YOA for pooled analyses of ZOSTER 006 and ZOSTER-022 will be considered as primary analysis for PHN. Overall PHN in subjects ≥ 50 YOA has become a secondary endpoint for pooled analyses of ZOSTER-006 and ZOSTER-022. The applicable objectives and endpoints have been updated accordingly in the ZOSTER-022 protocol. Pooled analyses of ZOSTER-006 and ZOSTER-022 will only be conducted if the primary objective [HZ vaccine efficacy (VE)] is demonstrated in both ZOSTER-006 and ZOSTER-022 separately.</p> <p>Regarding the reporting of SAEs that are related to study participation (e.g. protocol-mandated procedures, invasive tests, a change from existing therapy) or are related to a concurrent GSK medication/vaccine or any fatal SAE, it has been clarified that this includes SAEs that are considered by the investigator to be related to the investigational vaccine and are to be reported until study end.</p>

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported